{"schema_version":"1","generated_at":"2026-11-07T04:13:15.221Z","data_as_of":null,"url":"https://www.findmykol.com/kol/michael-axelson","json_url":"https://www.findmykol.com/kol/michael-axelson/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"michael-axelson","name":"Michael Axelson","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Tempus Labs","institution_url":"https://www.findmykol.com/institution/tempus-labs","city":"Charlotte","state":"NC","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1073615654","orcid":"0000-0001-9273-6936","openalex":"A5010192207"},"summary":"Michael Axelson is an Oncology physician affiliated with Tempus Labs. OpenAlex indexes 9 publications with 3,220 citations (h-index 5).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":9,"cited_by_count":3220,"h_index":5,"latest_activity_year":2021,"source":"works"},"payments":{"company_count":1,"program_years":{"first":2021,"last":null},"rows_total":1,"shown":1,"withheld":0,"rows":[{"payer":"Stryker Corporation","program_year":2021,"amount_usd":144.51,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1073615654"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1073615654","source":"payments"},"publications":{"total":9,"shown":5,"withheld":4,"matched_by":"OpenAlex author record","recent":[{"title":"Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data","year":2020,"journal":"Clinical Breast Cancer","source_url":"https://doi.org/10.1016/j.clbc.2020.11.012","status":"verified"},{"title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","year":2017,"journal":"The Lancet Oncology","source_url":"https://doi.org/10.1016/s1470-2045(17)30422-9","status":"verified"},{"title":"Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.","year":2016,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.3501","status":"verified"},{"title":"HPV16-E7 Expression Causes Fluorodeoxyuridine-mediated","year":2014,"status":"verified"},{"title":"U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma","year":2013,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-12-1956","status":"verified"}],"source":"works"},"contact":{"address_1":"2711 RANDOLPH RD","address_2":"SUITE 100","city":"Charlotte","state":"NC","zip":"282072034","phone":"704-342-1900","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1073615654","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":4}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2013-05-16","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}